Document:

Form of placement agen Warrant dated June 29, 2006

 Exhibit 10.11 
 Form of Placement Agent Warrant 
 THIS WARRANT AND THE SECURITIES ISSUABLE UPON EXERCISE HEREOF HAVE BEEN ACQUIRED FOR
INVESTMENT AND HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “ACT”), OR ANY STATE SECURITIES LAW. THIS WARRANT AND SUCH SECURITIES MAY NOT BE OFFERED, SOLD OR OTHERWISE PLEDGED, TRANSFERRED OR HYPOTHECATED IN
THE ABSENCE OF SUCH REGISTRATION OR DELIVERY OF AN OPINION OF COUNSEL IN FORM AND SUBSTANCE REASONABLY SATISFACTORY TO THE COMPANY THAT SUCH OFFER, SALE OR TRANSFER, PLEDGE OR HYPOTHECATION IS IN COMPLIANCE WITH THE ACT OR UNLESS SOLD IN FULL
COMPLIANCE WITH RULE 144 UNDER THE ACT. 
 INNOVIVE Pharmaceuticals, Inc. 
 Warrant for the Purchase of Shares of 
 Common Stock 
  

			
	No. 2006-[        ]	 	[            ] Shares

 FOR VALUE RECEIVED, INNOVIVE Pharmaceuticals, Inc., a Delaware corporation (the
“Company”), hereby certifies that [            ], its designee or its permitted assigns is entitled to purchase from the Company, at any time or from time to time
commencing on June 29, 2006 and prior to 5:00 P.M., New York City time, on June 29, 2013 (the “Exercise Period”), fully paid and non-assessable shares of common stock, $0.001 par value per share, of the Company for a
purchase price per share of $[4.36]. Hereinafter, (i) said common stock, $0.001 par value per share, of the Company, is referred to as the “Common Stock”; (ii) the shares of the Common Stock (subject to adjustment as set
forth herein) purchasable hereunder or under any other Warrant (as hereinafter defined) are referred to as the “Warrant Shares”; (iii) the aggregate purchase price payable for the Warrant Shares purchasable hereunder is
referred to as the “Aggregate Warrant Price”; (iv) the price payable (initially $4.36 per share subject to adjustment as set forth herein) for each of the Warrant Shares hereunder is referred to as the “Per Share
Warrant Price”; (v) this Warrant, any similar Warrants issued on the date hereof and any warrants hereafter issued in exchange or substitution for this Warrant or such similar Warrants are referred to as the
“Warrants”; (vi) the holder of this Warrant is referred to as the “Holder” and the holder of this Warrant and all other Warrants and Warrant Shares are referred to as the “Holders” and Holders
of more than fifty percent (50%) of the Warrant Shares then issuable upon exercise of then outstanding Warrants are referred to as the “Majority of the Holders”; and (vii) the then “Current Market Price”
per share of the Common Stock shall be deemed to be the last reported sale price of the Common 

 
Stock on the Trading Day (as defined below) immediately prior to such date or, in case no such reported sales take place on such day, the average of the last
reported bid and asked prices of the Common Stock on such day, in either case on the principal national securities exchange on which the Common Stock is admitted to trading or listed, or if not listed or admitted to trading on any such exchange, the
representative closing sale price of the Common Stock as reported by the National Association of Securities Dealers, Inc. Automated Quotations System (“NASDAQ”), or other similar organization if NASDAQ is no longer reporting such
information, or, if the Common Stock is not reported on NASDAQ, the per share sale price for the Common Stock in the over-the-counter market as reported by the National Quotation Bureau or similar organization, or if not so available, the fair
market value of the Common Stock as determined in good faith by the Company’s Board of Directors. A “Trading Day” shall mean any day on which shares of the Company’s Common Stock are sold, or eligible for sale, on the
respective exchange, quotation system or over-the-counter market. The Aggregate Warrant Price is not subject to adjustment. 
 This Warrant,
together with any warrants of like tenor, constituting in the aggregate Warrants to purchase [            ] Warrant Shares, was originally issued pursuant to a Placement Agency
Agreement dated as of March 28, 2006 (the “Agency Agreement”) between the Company and the Holder. 
 1. Exercise of Warrant.

 (a) This Warrant may be exercised in whole at any time, or in part from time to time, by the Holder during the Exercise Period:

 (i) by the surrender of this Warrant (with the subscription form at the end hereof duly executed) at the address set forth in subsection
9(a) hereof, together with proper payment of the Aggregate Warrant Price, or the proportionate part thereof if this Warrant is exercised in part, with payment for the Warrant Shares made by certified or official bank check payable to the order of,
or wire transfer of immediately available funds to, the Company; or 
 (ii) by the surrender of this Warrant (with the cashless exercise form
at the end hereof duly executed) (a “Cashless Exercise”) at the address set forth in subsection 9(a) hereof. Such presentation and surrender shall be deemed a waiver of the Holder’s obligation to pay the Aggregate Warrant
Price, or the proportionate part thereof if this Warrant is exercised in part. In the event of a Cashless Exercise, the Holder shall exchange its Warrant for that number of Warrant Shares subject to such Cashless Exercise multiplied by a fraction,
the numerator of which shall be the difference between the then Current Market Price and the Per Share Warrant Price, and the denominator of which shall be the then Current Market Price. For purposes of any computation under this subsection 1(a),
the then Current Market Price shall be based on the Trading Day immediately preceding such Cashless Exercise. 
 (b) If this Warrant is
exercised in part, this Warrant must be exercised for a number of whole shares of the Common Stock and the Holder is entitled to receive a new Warrant covering the Warrant Shares that have not been exercised and setting forth the proportionate part
of the Aggregate Warrant Price applicable to such Warrant Shares. Upon surrender of this Warrant in connection with the exercise of this Warrant pursuant to the terms hereof, the Company will (i) issue a certificate or certificates in the name
of the Holder for the 

 
largest number of whole shares of the Common Stock to which the Holder shall be entitled upon such exercise and, if this Warrant is exercised in whole, in
lieu of any fractional share of the Common Stock to which the Holder shall be entitled, pay to the Holder cash in an amount equal to the fair value of such fractional share (determined in such reasonable manner as the Board of Directors of the
Company shall determine), and (ii) deliver the other securities and properties receivable upon the exercise of this Warrant, or the proportionate part thereof, if this Warrant is exercised in part, pursuant to the provisions of this Warrant.

 2. Reservation of Warrant Shares; Listing. 
 The Company agrees that, prior to the expiration of this Warrant, the Company shall at all times (a) have authorized and in reserve, and shall keep available, solely for issuance and delivery upon the exercise of
this Warrant, the shares of the Common Stock and other securities and properties as from time to time shall be receivable upon the exercise of this Warrant, free and clear of all restrictions on sale or transfer, other than under Federal or state
securities laws, and free and clear of all preemptive rights and rights of first refusal and (b) if the Company hereafter lists its Common Stock on any national securities exchange, the NASDAQ National Market or the NASDAQ Capital Market, use
its commercially reasonable efforts to keep the Warrant Shares authorized for listing on such exchange upon notice of issuance. 
 3. Certain
Adjustments. 
 (a) In case the Company shall hereafter (i) pay a dividend or make a distribution on its Common Stock in shares
of Common Stock, (ii) subdivide its outstanding shares of Common Stock into a greater number of shares, (iii) combine or reverse-split its outstanding shares of Common Stock into a smaller number of shares or (iv) issue by
reclassification of its Common Stock any shares of capital stock of the Company, then the Per Share Warrant Price and the number of Warrant Shares shall forthwith be proportionately decreased and increased, respectively, in the case of a
subdivision, distribution or stock dividend, or proportionately increased and decreased, respectively, in the case of a combination or reverse stock split. The Aggregate Warrant Price payable for the then total number of Warrant Shares available for
exercise under this Warrant shall remain the same. Adjustments made pursuant to this subsection 3(a) shall become effective on the record date in the case of a dividend or distribution, and shall become effective immediately after the effective date
in the case of a subdivision, combination or reclassification. If such dividend, distribution, subdivision or combination is not consummated in full, the Per Share Warrant Price and Warrant Shares shall be readjusted accordingly. 
 (b) In case of any capital reorganization or reclassification, or any consolidation or merger to which the Company is a party other than a merger or
consolidation in which the Company is the continuing corporation, or in case of any sale or conveyance to another entity of all or substantially all of the assets of the Company, or in the case of any statutory exchange of securities with another
corporation (including any exchange effected in connection with a merger of a third corporation into the Company but excluding any exchange of securities or merger with another corporation in which the Company is a continuing corporation and that
does not result in any reclassification of or similar change in the Common Stock), the 

 
Holder of this Warrant shall have the right thereafter to receive on the exercise of this Warrant the kind and amount of securities, cash or other property
which the Holder would have owned or have been entitled to receive immediately after such reorganization, reclassification, consolidation, merger, statutory exchange, sale or conveyance had this Warrant been exercised immediately prior to the
effective date of such reorganization, reclassification, consolidation, merger, statutory exchange, sale or conveyance and in any such case, if necessary, appropriate adjustment shall be made in the application of the provisions set forth in this
Section 3 with respect to the rights and interests thereafter of the Holder of this Warrant to the end that the provisions set forth in this Section 3 shall thereafter correspondingly be made applicable, as nearly as may reasonably be, in
relation to any shares of stock or other securities or property thereafter deliverable on the exercise of this Warrant. The above provisions of this subsection 3(b) shall similarly apply to successive reorganizations, reclassifications,
consolidations, mergers, statutory exchanges, sales or conveyances. The Company shall require the issuer of any shares of stock or other securities or property thereafter deliverable on the exercise of this Warrant to be responsible for all of the
agreements and obligations of the Company hereunder. Notice of any such reorganization, reclassification, consolidation, merger, statutory exchange, sale or conveyance and of said provision so proposed to be made shall be mailed to the Holders of
Warrants not less than twenty (20) days prior to such event. A sale of all or substantially all of the assets of the Company for a consideration consisting primarily of securities shall be deemed a consolidation or merger for the foregoing
purposes. 
 (c) No adjustment in the Per Share Warrant Price shall be required unless such adjustment would require an increase or decrease
of at least $0.01 per share of Common Stock; provided, however, that any adjustments which by reason of this subsection 3(c) are not required to be made shall be carried forward and taken into account in any subsequent adjustment;
provided, further, however, that adjustments shall be required and made in accordance with the provisions of this Section 3 (other than this subsection 3(c)) not later than such time as may be required in order to preserve the
tax-free nature of a distribution, if any, to the Holder of this Warrant or Common Stock issuable upon the exercise hereof. All calculations under this Section 3 shall be made to the nearest cent or to the nearest 1/100th of a share, as the
case may be. Anything in this Section 3 to the contrary notwithstanding, the Company shall be entitled to make such reductions in the Per Share Warrant Price, in addition to those required by this Section 3, as it in its discretion shall
deem to be advisable in order that any stock dividend, subdivision of shares or distribution of rights to purchase stock or securities convertible or exchangeable for stock hereafter made by the Company to its stockholders shall not be taxable.

 (d) Whenever the Per Share Warrant Price or the number of Warrant Shares is adjusted as provided in this Section 3 and upon any
modification of the rights of a Holder of Warrants in accordance with this Section 3, the Company shall promptly prepare a brief statement of the facts requiring such adjustment or modification and the manner of computing the same and cause
copies of such certificate to be mailed to the Holders of the Warrants. The Company may, but shall not be obligated to unless requested by a Majority of the Holders, obtain, at its expense, a certificate of a firm of independent public accountants
of recognized standing selected by the Board of Directors (who may be the regular auditors of the Company) setting forth the Per Share Warrant Price and the number of Warrant Shares in effect after such adjustment or the effect of such modification,
a brief statement of the facts requiring such 

 
adjustment or modification and the manner of computing the same and cause copies of such certificate to be mailed to the Holders of the Warrants. 

(e) If the Board of Directors of the Company shall declare any dividend or other distribution with respect to the Common Stock other than a cash
distribution out of earned surplus, the Company shall mail notice thereof to the Holders of the Warrants not less than ten (10) days prior to the record date fixed for determining stockholders entitled to participate in such dividend or other
distribution. 
 (f) If, as a result of an adjustment made pursuant to this Section 3, the Holder of any Warrant thereafter surrendered
for exercise shall become entitled to receive shares of two or more classes of capital stock or shares of Common Stock and other capital stock of the Company, the Board of Directors (whose determination shall be conclusive and shall be described in
a written notice to the Holder of any Warrant promptly after such adjustment) shall determine, in good faith, the allocation of the adjusted Per Share Warrant Price between or among shares or such classes of capital stock or shares of Common Stock
and other capital stock. 
 (g) Upon the expiration of any rights, options, warrants or conversion privileges with respect to the issuance of
which an adjustment to the Per Share Warrant Price had been made, if such option, right warrant or conversion shall not have been exercised, the number of Warrant Shares purchasable upon exercise of this Warrant, to the extent this Warrant has not
then been exercised, shall, upon such expiration, be readjusted and shall thereafter be such as they would have been had they been originally adjusted (or had the original adjustment not been required, as the case may be) on the basis of
(A) the fact that Common Stock, if any, actually issued or sold upon the exercise of such rights, options, warrants or conversion privileges, and (B) the fact that such shares of Common Stock, if any, were issued or sold for the
consideration actually received by the Company upon such exercise plus the consideration, if any, actually received by the Company for the issuance, sale or grant of all such rights, options, warrants or conversion privileges whether or not
exercised; provided, however, that no such readjustment shall have the effect of decreasing the number of Warrant Shares purchasable upon exercise of this Warrant by an amount in excess of the amount of the adjustment initially made in
respect of the issuance, sale or grant of such rights, options, warrants or conversion privileges. 
 (h) In case any event shall occur as to
which the other provisions of this Section 3 are not strictly applicable but as to which the failure to make any adjustment would not fairly protect the purchase rights represented by this Warrant in accordance with the essential intent and
principles of the adjustments set forth in this Section 3 then, in each such case, the Board of Directors of the Company shall in good faith determine the adjustment, if any, on a basis consistent with the essential intent and principles
established herein, necessary to preserve the purchase rights represented by the Warrants. Upon such determination, the Company will promptly mail a copy thereof to the Holder of this Warrant and shall make the adjustments described therein.

 4. Fully Paid Stock; Taxes. The shares of the Common Stock represented by each and every certificate for Warrant Shares delivered on the
exercise of this Warrant shall, subject to compliance by the Holder with the terms hereof, at the time of such delivery, be duly authorized, 

 
validly issued and outstanding, fully paid and nonassessable, and not subject to preemptive rights or rights of first refusal imposed by any agreement to
which the Company is a party, and the Company will take all such actions as may be necessary to assure that the par value, if any, per share of the Common Stock is at all times equal to or less than the then Per Share Warrant Price. The Company
shall pay, when due and payable, any and all Federal and state stamp, original issue or similar taxes which may be payable in respect of the issue of any Warrant Share or any certificate thereof to the extent required because of the issuance by the
Company of such security. 
 5. Registration Under Securities Act of 1933. 
 The Holder shall have the right to participate in the registration rights granted to purchasers of Series A Convertible Preferred Stock, $0.001 par value
per share (the “Preferred Stock”), of the Company pursuant to Section 5 of the Subscription Agreement (the “Subscription Agreement”) entered into between each such purchaser and the Company in connection with
the issuance and sale of the Preferred Stock on or about the date hereof, to the same extent as if the Holder were a party thereto. The Company shall have the same obligations to the Holder as it has under Section 5 of the Subscription
Agreement to the “Subscribers” and the “Holders” thereunder, and the Holder shall be entitled to enforce such obligations against the Company as if the Holder were a party thereto. By acceptance of this Warrant, the Holder agrees
to comply with the provisions in Section 5 of the Subscription Agreement to the same extent as if it were a party thereto. 
 6. Investment
Intent; Limited Transferability.  
 (a) By accepting this Warrant, the Holder represents to the Company that it understands that this
Warrant and any securities obtainable upon exercise of this Warrant have not been registered for sale under Federal or state securities laws and are being offered and sold to the Holder pursuant to one or more exemptions from the registration
requirements of such securities laws. In the absence of an effective registration of such securities or an exemption therefrom, any certificates for such securities shall bear the legend set forth on the first page hereof; provided however, that
following the effective date of the Registration Statement (as such term is defined in the Subscription Agreement), such legend may, at the request of the Holder, be removed from the certificates evidencing such Warrant Shares prior to the resale
thereof and the Company will rescind any stop transfer orders with respect to such shares given to the Company’s transfer agent, provided that the Holder represents and covenants to the Company in writing (in a form reasonably acceptable to the
Company and its counsel) that (1) such Holder will sell such Warrant Shares only pursuant to and in the manner contemplated by the Registration Statement, including the Plan of Distribution section contained therein, and otherwise in compliance
with the Act, including the prospectus delivery requirements of such Act, (2) the Holder will indemnify the Company for any damages or losses resulting to the Company for the Holder’s breach of its representation and covenant described in
the foregoing clause (1), and (3) such other agreements or covenants as the Company or its counsel may reasonably request. Subject to the foregoing, at such time and to the extent a legend is no longer required for the Warrant Shares, the
Company will use its best efforts to no later than three (3) trading days following the delivery to the Company or the Company’s transfer agent by the holder of such Warrant Shares of a legended certificate representing such Warrant Shares

 
(together with such accompanying documentation or representations as reasonably required by counsel to the Company), deliver or cause to be delivered a
certificate representing such Warrant Shares that is free from the foregoing legend. The Holder understands that it must bear the economic risk of its investment in this Warrant and any securities obtainable upon exercise of this Warrant for an
indefinite period of time, as this Warrant and such securities have not been registered under Federal or state securities laws and therefore cannot be sold unless subsequently registered under such laws, unless an exemption from such registration is
available. The Holder further represents to the Company, by accepting this Warrant, that it has full power and authority to accept this Warrant and make the representations set forth herein. 
 (b) The Holder, by its acceptance of this Warrant, represents to the Company that it is acquiring this Warrant and will acquire any securities obtainable
upon exercise of this Warrant for its own account for investment and not with a view to, or for sale in connection with, any distribution thereof in violation of the Act. The Holder agrees, by acceptance of this Warrant, that this Warrant and any
such securities issuable under this Warrant will not be sold or otherwise transferred unless (i) a registration statement with respect to such transfer is effective under the Act and any applicable state securities laws or (ii) such sale
or transfer is made pursuant to one or more exemptions from the Act. 
 (c) In addition to the limitations set forth in Section 1 and in
accordance with the legend on the first page hereof, this Warrant may not be sold, transferred, assigned or hypothecated by the Holder except in compliance with the provisions of the Act and the applicable state securities “blue sky” laws,
and is so transferable only upon the books of the Company which it shall cause to be maintained for such purpose. The Company may treat the registered Holder of this Warrant as it appears on the Company’s books at any time as the Holder for all
purposes. The Company shall permit any Holder of a Warrant or its duly authorized attorney, upon written request during ordinary business hours, to inspect and copy or make extracts from its books showing the registered Holders of Warrants. All
Warrants issued upon the transfer or assignment of this Warrant will be dated the same date as this Warrant, and all rights of the holder thereof shall be identical to those of the Holder unless, in each case, otherwise prohibited by applicable law.

 (d) The Holder has been afforded (i) the opportunity to ask such questions as it has deemed necessary of, and to receive answers
from, representatives of the Company concerning the terms and conditions of the Warrants or the exercise of the Warrants; and (ii) the opportunity to request such additional information which the Company possesses or can acquire without
unreasonable effort or expense. 
 (e) The Holder did not (i) receive or review any advertisement, article, notice or other
communication published in a newspaper or magazine or similar media or broadcast over television or radio, whether closed circuit, or generally available; or (ii) attend any seminar, meeting or investor or other conference whose attendees were,
to such Holder’s knowledge, invited by any general solicitation or general advertising. 
 (f) The Holder is an “accredited
investor” within the meaning of Regulation D under the Act. Such Holder is acquiring the Warrants for its own account and not with a 

 
present view to, or for sale in connection with, any distribution thereof in violation of the registration requirements of the Act, without prejudice,
however, to such Holder’s right, subject to the provisions of the Placement Agency Agreement and this Warrant, at all times to sell or otherwise dispose of all or any part of such Warrants and Warrant Shares. 
 (g) Either by reason of such Holder’s business or financial experience or the business or financial experience of its professional advisors (who are
unaffiliated with and who are not compensated by the Company or any affiliate, finder or selling agent of the Company, directly or indirectly), such Holder has the capacity to protect such Holder’s interests in connection with the transactions
contemplated by this Warrant and the Placement Agency Agreement. The Holder, by its acceptance of this Warrant, represents to the Company that it is able to fend for itself, can bear the economic risk of its investment and has such knowledge and
experience in financial or business matters that it is capable of evaluating the merits and risks of the investment in this Warrant. Holder also represents it has not been organized for the purpose of acquiring this Warrant. 
 7. Loss, etc., of Warrant. Upon receipt of evidence reasonably satisfactory to the Company of the loss, theft, destruction or mutilation of this Warrant,
and of indemnity reasonably satisfactory to the Company, if lost, stolen or destroyed, and upon surrender and cancellation of this Warrant, if mutilated, the Company shall execute and deliver to the Holder a new Warrant of like date, tenor and
denomination. 
 8. Warrant Holder Not Stockholder. This Warrant does not confer upon the Holder any right to vote on or consent to or receive
notice as a stockholder of the Company, as such, in respect of any matters whatsoever, nor any other rights or liabilities as a stockholder, prior to the exercise hereof; this Warrant does, however, require certain notices to Holders as set forth
herein. 
 9. Communication. No notice or other communication under this Warrant shall be effective or deemed to have been given unless, the
same is in writing and is mailed by first-class mail, postage prepaid, or via recognized overnight courier with confirmed receipt, addressed to: 
 (a) the Company at INNOVIVE Pharmaceuticals, Inc., 555 Madison Avenue, 25th Floor, New York, NY 10022, Attn: President, or other such address as the Company has designated in writing to the Holder; or 
 (b) the Holder, c/o [            ], or other such address as the Holder
has designated in writing to the Company. 
 10. Headings. The headings of this Warrant have been inserted as a matter of convenience and shall
not affect the construction hereof. 
 11. Applicable Law. This Warrant shall be governed by and construed in accordance with the law of the
State of New York without giving effect to the principles of conflicts of law thereof. 

 12. Amendment, Waiver, etc. Except as expressly provided herein, neither this Warrant nor any term hereof
may be amended, waived, discharged or terminated other than by a written instrument signed by the party against whom enforcement of any such amendment, waiver, discharge or termination is sought; provided, however, that any provisions hereof may be
amended, waived, discharged or terminated upon the written consent of the Company and the Majority of the Holders. 
 *  
*   *   *   * 

 IN WITNESS WHEREOF, the Company has caused this Warrant to be signed by the undersigned duly
authorized officer as of June 29, 2006. 
  

			
	INNOVIVE Pharmaceuticals, Inc.
		
	By:	 	  
	Name:	 	  
	Title:	 	  

 SUBSCRIPTION (cash) 
 The undersigned, ___________________, pursuant to the provisions of the foregoing Warrant, hereby agrees to subscribe for and purchase
____________________ shares of the Common Stock, par value $0.001 per share, of INNOVIVE Pharmaceuticals, Inc. covered by said Warrant, and makes payment therefor in full at the price per share provided by said Warrant. 
  

									
					
	Dated:	 	  	 		 	 Signature:
	 	  
					
		 		 		 	 Address:
	 	  

 CASHLESS EXERCISE 
 The undersigned _____________, pursuant to the provisions of the foregoing Warrant, hereby elects to exchange its Warrant for ___________________ shares
of Common Stock, par value $0.001 per share, of INNOVIVE Pharmaceuticals, Inc. pursuant to the Cashless Exercise provisions of the Warrant. 
  

									
					
	Dated:	 	  	 		 	 Signature:
	 	  
					
		 		 		 	 Address:
	 	  

 ASSIGNMENT 
 FOR VALUE RECEIVED _______________ (“Assignor”) hereby sells, assigns and transfers unto ____________________ (“Transferee”) the foregoing Warrant and all rights evidenced thereby, and does
irrevocably constitute and appoint _____________________, attorney, to transfer said Warrant on the books of INNOVIVE Pharmaceuticals, Inc. By acceptance of the foregoing Warrant, Transferee shall become a Holder under said Warrant and subject to
the rights, obligations and representations of Holder set forth in said Warrant. 
 ASSIGNOR: 
  

									
					
	Dated:	 	  	 		 	 Signature:
	 	  
					
		 		 		 	 Address:
	 	  

 TRANSFEREE: 
  

									
					
	Dated:	 	  	 		 	 Signature:
	 	  
					
		 		 		 	 Address:
	 	  

 PARTIAL ASSIGNMENT 
 FOR VALUE RECEIVED _______________ (“Assignor”) hereby assigns and transfers unto ____________________ (“Transferee”) the right to
purchase _______ shares of Common Stock, par value $0.001 per share, of INNOVIVE Pharmaceuticals, Inc. covered by the foregoing Warrant, and a proportionate part of said Warrant and the rights evidenced thereby, and does irrevocably constitute and
appoint ____________________, attorney, to transfer such part of said Warrant on the books of INNOVIVE Pharmaceuticals, Inc. By acceptance of the proportionate part of foregoing Warrant, Transferee shall become a Holder under said proportionate part
of said Warrant and subject to the rights, obligations and representations of Holder set forth in said Warrant. 
 ASSIGNOR:

  

									
					
	Dated:	 	  	 		 	 Signature:
	 	  
					
		 		 		 	 Address:
	 	  

 TRANSFEREE: 
  

									
					
	Dated:	 	  	 		 	 Signature:
	 	  
					
		 		 		 	 Address:Ameded and Restated Certificate of Incorporation

 Exhibit 10.12 
 AMENDED AND RESTATED 
 CERTIFICATE OF INCORPORATION 
 OF 
 INNOVIVE PHARMACEUTICALS, INC.

 Innovive Pharmaceuticals, Inc. (the “Corporation”), a corporation organized and existing under and by virtue of the
General Corporation Law of the State of Delaware, does hereby certify as follows: 
 1. The name of the Corporation is Innovive
Pharmaceuticals, Inc. The date of the filing of its original Certificate of Incorporation with the Secretary of State of the State of Delaware was March 24, 2004 under the name “Broadway Therapeutics, Inc.” 
 2. This Amended and Restated Certificate of Incorporation was duly adopted by unanimous written consent of the board of directors and written consent of
the stockholders of the Corporation in accordance with the applicable provisions of Sections 141, 228, 242 and 245 of the General Corporation Law of the State of Delaware. 
 3. This Amended and Restated Certificate of Incorporation restates, integrates and amends the Certificate of Incorporation filed March 24, 2004, as
amended on September 20, 2004, and the text of the Certificate of Incorporation is hereby amended and restated in its entirety to read as herein set forth in full: 
 FIRST: The name of this corporation (herein called the “Corporation”) shall be: “Innovive Pharmaceuticals, Inc.” 
 SECOND: The address of the registered office of the Corporation in the State of Delaware is 2711 Centerville Road, Suite 400, in the City of
Wilmington, County of New Castle 19808. The name of the registered agent of the Corporation at such address is Corporation Service Company. 
 THIRD: The purpose or purposes of the Corporation shall be to engage in any lawful act or activity for which corporations may be organized under the General Corporation Law of the State of Delaware. 
 FOURTH: The total number of shares of stock which this Corporation is authorized to issue is Thirty-Five Million (35,000,000) shares,
consisting of the following two classes: (i) Twenty-Five Million (25,000,000) shares of common stock, $0.001 par value per share (the “Common Stock”), and (ii) Ten Million (10,000,000) shares of Series A
Convertible Preferred Stock, $0.001 par value per share (the “Series A Preferred Stock”). 
 The number of authorized shares
of any class or classes of stock may be increased or decreased (but not below the number of shares then outstanding) by the affirmative vote of a majority 

 
in voting power of the outstanding capital stock of the Corporation entitled to vote thereon irrespective of the provisions of Section 242(b)(2) of the
General Corporation Law of the State of Delaware. 
 The designations, powers, preferences and relative participating, optional or other
special rights, and the qualifications, limitations and restrictions thereof, with respect to the Common Stock and the Series A Preferred Stock, are as follows: 
 1. Ranking. The Series A Preferred Stock shall, with respect to dividend rights, have the entitlements set forth herein and shall, with respect to rights on liquidation, dissolution and winding up of the
affairs of the Corporation, rank senior to all classes of Common Stock of the Corporation and, subject to the rights of any series of Preferred Stock that may from time to time come into existence providing that the Series A Preferred Stock shall
rank junior thereto, other equity securities of the Corporation. The Common Stock and any other stock ranking (with respect to dividends, or on liquidation, dissolution and winding up of the affairs of the Corporation) junior to the Series A
Preferred Stock shall be referred to hereinafter collectively as “Junior Stock”. 
 2. Dividends and Distributions.

 (a) Subject to the prior and superior rights of the holders of any shares of any series or class of capital stock ranking prior and
superior to the shares of Series A Preferred Stock with respect to dividends, the holders of shares of Series A Preferred Stock shall be entitled to receive, when, as and if declared by the Board of Directors (the “Board”), out of
assets legally available for that purpose, dividends or distributions in cash, stock or otherwise. Any reference to “distribution” contained in this Section 2, unless noted otherwise, shall not include any distribution made in
connection with any liquidation, dissolution or winding up of the Corporation, whether voluntary or involuntary. 
 (b) If and when the
Corporation shall declare any dividend or distribution on any Junior Stock, the Corporation shall, concurrently with the declaration of such dividend or distribution on the Junior Stock, declare a like dividend or distribution, as the case may be,
on the Series A Preferred Stock in an amount per share equal to (i) the amount of the dividend or distribution per share of Junior Stock (or, if the Junior Stock is directly or indirectly convertible into Common Stock, per share of Common Stock
into which such Junior Stock is then convertible) multiplied by (ii) the number of shares of Common Stock into which one share of Series A Preferred Stock is then convertible. Any dividend or distribution declared on the Series A Preferred
Stock pursuant to this Section 2(b) shall be paid to the holders thereof at the same time as the dividend or distribution on the Junior Stock by which it is measured is paid. 
 (c) No dividend or distribution, as the case may be, may be declared on any Junior Stock unless a dividend or distribution, as the case may be, is
declared on the Series A Preferred Stock in accordance with Section 2(b) above. 
 (d) All dividends or distributions declared upon the
Series A Preferred Stock shall be declared pro rata per share. 

 (e) So long as any shares of the Series A Preferred Stock are outstanding, no other stock of the
Corporation ranking on a parity with or junior to the Series A Preferred Stock as to dividends or distributions or otherwise upon liquidation, dissolution or winding up shall be redeemed, purchased or otherwise acquired for any consideration (or any
moneys be paid to or made available for a sinking fund or otherwise for the purchase or redemption of any shares of any such stock), other than purchases pursuant to repurchase agreements with employees or the Corporation’s stock option plan,
by the Corporation unless all dividends and distributions, if any, accrued but unpaid on all outstanding shares of the Series A Preferred Stock shall have been paid or set apart for payment. 
 (f) So long as any shares of the Series A Preferred Stock are outstanding, no dividends or distributions, except as described in the next succeeding
sentence, shall be declared or paid or shall be set apart for payment on any class or series of stock of the Corporation ranking, as to dividends or distributions, on a parity with or junior to the Series A Preferred Stock, for any period unless all
dividends have been or contemporaneously are declared and paid, or declared and a sum sufficient for the payment thereof set apart for such payment, on the Series A Preferred Stock. When dividends or distributions are not paid in full or a sum
sufficient for such payment is not set apart, as aforesaid, upon the shares of the Series A Preferred Stock and any other class or series of stock ranking on a parity as to dividends with the Series A Preferred Stock, all dividends and distributions
declared upon such other stock shall be declared pro rata with the Series A Preferred Stock so that the amounts of dividends or distributions per share declared on the Series A Preferred Stock and such other stock shall in all cases bear to each
other the same ratio that accrued dividends or such distributions per share on the shares of the Series A Preferred Stock and on such other stock bear to each other. 
 3. Liquidation Preference. (a) In the event of a (i) liquidation, dissolution or winding up of the Corporation, whether voluntary or involuntary or (ii) voluntary or involuntary bankruptcy of the
Corporation (subparagraphs (i) and (ii) being collectively referred to as a “Liquidation Event”), after payment or provision for payment of debts and other liabilities of the Corporation, the holders of the Series A
Preferred Stock then outstanding shall be entitled to be paid out of the assets of the Corporation available for distribution to its stockholders, whether such assets are capital, surplus, or earnings, before and in preference to any payment (or
declaration and setting apart for payment) in respect of any Junior Stock, an amount equal to $3.96 (the “Stated Value “) plus an amount equal to all declared and unpaid dividends thereon. If upon any Liquidation Event, the assets
to be distributed to the holders of the Series A Preferred Stock shall be insufficient to permit the payment to such stockholders of the full preferential amounts aforesaid, then all of the assets of the Corporation to be distributed shall be so
distributed ratably to the holders of the Series A Preferred Stock on the basis of the number of shares of Series A Preferred Stock held. Subject to Section 4(e), a consolidation or merger of the Corporation with or into another privately held
corporation in which the Corporation is not the surviving entity or the shares of Common Stock of the Corporation constituting in excess of 50% of the voting power of the Corporation are exchanged for or changed into other stock or securities, cash
and/or any other property or a sale of all or substantially all the assets of the Corporation shall not be considered a Liquidation Event and, accordingly, if securities are to be issued to the holders of the Series A Preferred Stock the 

 
Corporation shall make appropriate provision to ensure that the terms of this Certificate of Designations survive any such transaction. For purposes of
clarity, in the event of a consolidation or merger with a publicly traded corporation then the Series A Preferred Stock shall convert to Common Stock in accordance with Section 4(d). All shares of Series A Preferred Stock shall rank as to
payment upon the occurrence of any Liquidation Event senior to the Common Stock as provided herein and, unless the terms of such other series shall provide otherwise, senior to all other series of the Corporation’s preferred stock. 

(b) Upon the completion of the distribution required by subparagraph (a) of this Section 3 and subject to any other distribution that may be
required with respect to any series of Preferred Stock that may from time to time come into existence, the remaining assets of the Corporation available for distribution to stockholders shall be distributed among the holders of Common Stock pro rata
based on the number of shares of Common Stock held by the holders of Common Stock. 
 (c) Any securities or other property to be delivered to
the holders of the Series A Preferred Stock pursuant to Section 3(a) hereof shall be valued as follows: 
 (i) Securities not subject to
an investment letter or other similar restriction on free marketability: 
 (A) If traded on a securities exchange or on
NASDAQ (as defined below), or if actively traded over-the-counter, the value shall be deemed to be the Market Price (as defined below) of the securities as of the date of valuation. 
 (B) If there is no such active public market for the securities, the value shall be the Fair Market Value (as defined below) of the
securities. 
 (ii) Securities subject to an investment letter or other similar restriction on free marketability shall be valued at the Fair
Market Value. 
 (iii) The “Market Price” of a security shall mean the volume weighted average price of such security, for 10
consecutive trading days, ending with the day prior to the date as of which the Market Price is being determined, calculated by adding up the dollars traded for every transaction (price multiplied by the number of shares traded) and then dividing by
the total shares traded for the day. 
 (iv) The “Fair Market Value” of any asset (including any security) means the fair market
value thereof as determined by the Board in good faith. 
 4. Conversion. 
 (a) Right to Convert. The shares of Series A Preferred Stock shall be convertible, in whole or in part, at the option of the holder thereof and
upon notice to the Corporation as set forth in Section 4(c) below, into fully paid and nonassessable shares of Common Stock and such other 

 
securities and property as hereinafter provided. The initial conversion price per share of Common Stock is the Stated Value (the “Conversion
Price”) and shall be subject to adjustment as provided herein. The rate at which each share of Series A Preferred Stock is convertible at any time into Common Stock (the “Conversion Rate”) shall be determined by dividing
the Stated Value by the then existing Conversion Price. 
 (b) Dividends Upon Conversion. Upon conversion, all accrued and unpaid
dividends (whether or not declared) on the Series A Preferred Stock, if any, shall be canceled. 
 (c) Conversion Procedures. (1) a.
Any holder of shares of Series A Preferred Stock desiring to convert such shares into Common Stock pursuant to Section 4(a) hereof shall surrender the certificate or certificates evidencing such shares of Series A Preferred Stock at the office
of the transfer agent for the Series A Preferred Stock (the “Transfer Agent”), which certificate or certificates, if the Corporation shall so require, shall be duly endorsed to the Corporation or in blank, or accompanied by proper
instruments of transfer to the Corporation or in blank, accompanied by irrevocable written notice to the Corporation that the holder elects so to convert such shares of Series A Preferred Stock and specifying the name or names (with address) in
which a certificate or certificates evidencing shares of Common Stock are to be issued. The Corporation need not deem a notice of conversion to be received unless the holder complies with all the provisions hereof. The Corporation will instruct the
Transfer Agent (which may be the Corporation) to make a notation of the date that a notice of conversion is received, which date shall be deemed to be the date of receipt for purposes hereof, so long as receipt is prior to 4:00 p.m. Eastern Standard
Time on a day during which the national securities exchanges are open for trading (a “Trading Day”) and otherwise shall be deemed to be received on the next following Trading Day. 
 (2) The Corporation shall, as soon as practicable after such deposit of certificates evidencing shares of Series A Preferred Stock accompanied by the
written notice and compliance with any other conditions herein contained, deliver to the person for whose account such shares of Series A Preferred Stock were so surrendered, or to the nominee or nominees of such person, certificates evidencing the
number of full shares of Common Stock to which such person shall be entitled as aforesaid, together with a cash adjustment of any fraction of a share as hereinafter provided. Subject to the following provisions of this paragraph, such conversion
shall be deemed to have been made as of the date of receipt (in accordance with the third sentence of Section 4(c)(1) hereof) of the shares of Series A Preferred Stock to be converted, and the person or persons entitled to receive the Common
Stock deliverable upon conversion of such Series A Preferred Stock shall be treated for all purposes as the record holder or holders of such Common Stock on such date; provided, however, that the Corporation shall not be required to
convert any shares of Series A Preferred Stock while the stock transfer books of the Corporation are closed for any purpose, but the surrender of Series A Preferred Stock for conversion during any period while such books are so closed shall become
effective for conversion immediately upon the reopening of such books as if the surrender had been made on the date of such reopening, and the conversion shall be at the Conversion Rate in effect on such date. 
 (3) All notices of conversion shall be irrevocable; provided, however, that if the Corporation has sent notice of an event pursuant to
Section 4(h) hereof, a holder of Series A 

 
Preferred Stock may, at its election, provide in its notice of conversion that the conversion of its shares of Series A Preferred Stock shall be contingent
upon the occurrence of the record date or effectiveness of such event (as specified by such holder), provided that such notice of conversion is received by the Corporation prior to such record date or effective date, as the case may be. 

(d) Automatic Conversion. Each share of Series A Preferred Stock shall be automatically converted into shares of Common Stock at the Conversion
Rate, subject to adjustments as hereinafter provided, upon the effectiveness of a registration statement on an appropriate form registering the resale of such shares of Series A Preferred Stock or the shares of Common Stock into which such shares of
Series A Preferred Stock are convertible. 
 (e) Adjustment of Conversion Rate and Conversion Price. 
 (i) Subject in all events to Section 4(d), in case of any (i) reclassification, capital reorganization or other change of outstanding shares of
Common Stock, or in case of any consolidation or merger of the Corporation with or into another entity (other than a consolidation or merger in which the Corporation is the continuing entity and which does not result in any reclassification, capital
reorganization or other change of outstanding shares of Common Stock other than the number thereof), or any (ii) sale or conveyance to another entity of the assets of the Corporation as, or substantially as, an entirety (other than a
sale/leaseback, mortgage or other financing transaction), then the Corporation shall cause effective provision to be made so that each holder of a share of Series A Preferred Stock shall be entitled to receive, upon conversion of such share of
Series A Preferred Stock, the kind and number of shares of stock or other securities or property (including cash) receivable upon such reclassification, capital reorganization or other change, consolidation, merger, sale or conveyance by a holder of
the number of shares of Common Stock into which such share of Series A Preferred Stock was convertible immediately prior to such reclassification, capital reorganization or other change, consolidation, merger, sale or conveyance. Any such provision
shall include a provision for adjustments that shall be as nearly equivalent as may be practicable to the adjustments provided for in this Section 4(e). The Corporation shall not effect any such reclassification, capital reorganization or other
change, consolidation, merger, sale or conveyance unless prior to or simultaneously with the consummation thereof the successor (if other than the Corporation) resulting from such transaction or the entity purchasing assets or other appropriate
entity shall assume, by written instrument executed and delivered to the Transfer Agent, the obligation to deliver to the holder of each share of Series A Preferred Stock such shares of stock, securities or assets as, in accordance with the
foregoing provisions, such holders may be entitled to receive and the other obligations under this Certificate of Designations. The foregoing provisions shall similarly apply to successive reclassifications, capital reorganizations and other changes
of outstanding shares of Common Stock and to successive consolidations, mergers, sales or conveyances. 
 (ii) If the Corporation shall, at
any time or from time to time after the issuance from the Corporation to the applicable holder of the Series A Preferred Stock, sell or grant any Common Stock, any evidences of indebtedness, shares or other securities directly or indirectly
convertible into or exchangeable for Common Stock (“Convertible Securities”), any rights, options or warrants to purchase or otherwise acquire Common Stock or any Convertible Securities, in each 

 
case for a price per share or entitling the holders thereof to purchase Common Stock at a price per share (determined by dividing (i) the total amount,
if any, received or receivable by the Corporation in consideration of the issuance or sale of such securities plus the total consideration, if any, payable to the Corporation upon exercise or conversion thereof (the “Total
Consideration”) by (ii) the number of additional shares of Common Stock issuable upon exercise or conversion of such securities) which is less than the Conversion Price in effect on the date of such issuance or sale, then the
Conversion Price shall be adjusted by multiplying the Conversion Price then in effect by a fraction, the numerator of which shall be (x) the sum of (A) the number of shares of Common Stock (on an as converted, fully diluted basis assuming
conversion of all Convertible Securities) outstanding on the record date of such issuance or sale plus (B) the Total Consideration divided by the current Conversion Price, and the denominator of which shall be (y) the number of shares of
Common Stock (on an as converted, fully diluted basis assuming conversion of all Convertible Securities) outstanding on the record date of such issuance or sale plus the maximum number of additional shares of Common Stock issued, sold or issuable
upon exercise or conversion of such securities This Section 4(e)(ii) shall only be applicable to the (x) sale of securities for cash by the Corporation in a private financing transaction (including a private placement of
securities) or (y) a merger or acquisition in which the holders of the Corporation’s securities immediately prior to such transaction hold less than a majority of the voting securities of the surviving entity immediately subsequent to the
transaction, and shall not apply, and the Holder of Series A Preferred Stock shall not be entitled to an adjustment in the Conversion Price pursuant to this Section 4(e)(ii), in the event that the Corporation issues Common Stock
or other Convertible Securities at a price per share that is less than the Conversion Price, if such issuance is a result of a transaction consummated for purposes other than financing, which shall include, but not be limited to (i) the
issuance of securities upon the exercise or conversion of Convertible Securities already in existence as of the date of original issuance of the Series A Preferred Stock by the Corporation to the initial Holder; (ii) a stock split, reverse
stock split or other recapitalization of the Corporation; (iii) a merger, acquisition or strategic alliance of the Corporation with another company, including any licensing transaction or joint venturein, in which the holders of the
Corporation’s securities immediately prior to such transaction hold at least a majority of the voting securities of the surviving entity immediately subsequent to the transaction; (iv) dividends or other capital distributions;
(v) exercise or conversion of placement warrants or options issued to any placement agent of the Corporation or any broker or consultant of the Corporation in return for providing services to the Corporation; and (vi) shares of Common
Stock issued pursuant to the exercise of options and other stock rights granted pursuant to the Company’s employee stock option plan. 
 (f) No Fractional Shares. No fractional shares or scrip representing fractional shares of Common Stock shall be issued upon conversion of Series A Preferred Stock. If more than one certificate evidencing shares of Series A
Preferred Stock shall be surrendered for conversion at one time by the same holder, the number of full shares issuable upon conversion thereof shall be computed on the basis of the aggregate number of shares of Series A Preferred Stock so
surrendered. Instead of any fractional share of Common Stock which would otherwise be issuable upon conversion of any shares of Series A Preferred Stock, the Corporation shall pay a cash adjustment in respect of such fractional interest in an amount
equal to the same fraction of the fair market value (valued pursuant to Section 3(c) hereof) as of the close of business on the day of conversion. 

         (g) Reservation of Shares; Transfer Taxes; Etc. The
Corporation shall at all times reserve and keep available, out of its authorized and unissued shares of Common Stock, solely for the purpose of effecting the conversion of the Series A Preferred Stock, including shares of Series A Preferred Stock
issued as payment of dividends pursuant to Section 2 hereof, such number of shares of its Common Stock free of preemptive rights as shall be sufficient to effect the conversion of all shares of Series A Preferred Stock from time to time
outstanding. The Corporation shall use its best efforts from time to time, in accordance with the laws of the State of Delaware, to increase the authorized number of shares of Common Stock if at any time the number of shares of authorized, unissued
and unreserved Common Stock shall not be sufficient to permit the conversion of all the then-outstanding shares of Series A Preferred Stock. 
 (h) Prior Notice of Certain Events. In case: 
 (i) the Corporation shall declare any dividend (or any other
distribution); or 
 (ii) the Corporation shall authorize the granting to the holders of Common Stock of rights or warrants to subscribe for
or purchase any shares of stock of any class or of any other rights or warrants; or 
 (iii) of any reclassification of Common Stock (other
than a subdivision or combination of the outstanding Common Stock, or a change in par value, or from par value to no par value, or from no par value to par value); or 
 (iv) of any consolidation or merger to which the Corporation is a party and for which approval of any stockholders of the Corporation shall be required, or of the sale or transfer of all or substantially all of the
assets of the Corporation or of any compulsory share exchange whereby the Common Stock is converted into other securities, cash or other property; or 
 (v) of the voluntary or involuntary dissolution, liquidation or winding up of the Corporation (including, without limitation, a Liquidation Event); 
 then the Corporation shall cause to be filed with the Transfer Agent for the Series A Preferred Stock, and shall cause to be mailed to the holders of record of the Series A Preferred Stock, at their last addresses as
they shall appear upon the stock transfer books of the Corporation, at least 20 days prior to the applicable record date hereinafter specified, a notice stating (x) the date on which a record (if any) is to be taken for the purpose of such
dividend, distribution or granting of rights or warrants or, if a record is not to be taken, the date as of which the holders of Common Stock of record to be entitled to such dividend, distribution, rights or warrants are to be determined and a
description of the cash, securities or other property to be received by such holders upon such dividend, distribution or granting of rights or warrants or (y) the date on which such reclassification, consolidation, merger, sale, transfer, share
exchange, dissolution, liquidation or winding up or other Liquidation Event is expected to become effective, the date as of which it is expected that holders of Common Stock of record shall be entitled to exchange their shares of Common Stock for
securities or other property deliverable upon such exchange, dissolution, liquidation or winding up or other Liquidation Event 

 
and the consideration, including securities or other property, to be received by such holders upon such exchange; provided, however, that no failure
to mail such notice or any defect therein or in the mailing thereof shall affect the validity of the corporate action required to be specified in such notice. 
 (i) Ambiguities/Errors. The Board shall have the power to resolve any ambiguity or correct any error in the provisions relating to the convertibility of the Series A Preferred Stock, and its actions in
so doing shall be final and conclusive. 
 5. Voting Rights. 
 (a) General. Except as otherwise provided herein or in the Bylaws of the Corporation, the holders of shares of Series A Preferred Stock, the
holders of shares of Common Stock and the holders of any other class or series of shares entitled to vote with the Common Stock shall vote together as one class on all matters submitted to a vote of stockholders of the Corporation. In any such vote,
each share of Series A Preferred Stock shall entitle the holder thereof to cast the number of votes equal to the number of votes which could be cast in such vote by a holder of the Common Stock into which such share of Series A Preferred Stock is
convertible on the record date for such vote, or if no record date has been established, on the date such vote is taken. Any shares of Series A Preferred Stock held by the Corporation or any entity controlled by the Corporation shall not have voting
rights hereunder and shall not be counted in determining the presence of a quorum. 
 (b) Class Voting Rights. In addition to any vote
specified in Section 5(a), so long as at least 50% of the Series A Preferred Stock issued shall be outstanding, the affirmative vote or consent of the holders of at least 66% of all outstanding Series A Preferred Stock voting separately as a
class shall be necessary to permit, effect or validate any one or more of the following: (i) the amendment, alteration or repeal of any provision of the Certificate of Incorporation or the Bylaws of the Corporation so as adversely to affect the
relative rights, preferences, qualifications, limitations or restrictions of the Series A Preferred Stock (including without limitation any amendment of this Section 5), (ii) the declaration or payment of any dividend or distribution on
any Junior Stock, or the authorization of the repurchase of any securities of the Corporation (other than pursuant to repurchase agreements with employees or the Corporation’s stock option plan), (iii) the authorization, issuance or
increase of any security ranking senior to the Series A Preferred Stock and (iv) the approval of any liquidation or dissolution of the Corporation. The class vote as contemplated herein shall specifically not be required for (x) issuances
of Common Stock, or (y) any consolidation or merger of the Corporation with or into another corporation, whether or not the Corporation is the surviving entity, a sale or transfer of all or part of the Corporation’s assets for cash,
securities or other property, or a compulsory share exchange. 
 6. Redemption. The Corporation shall not have the right to purchase,
call, redeem or otherwise acquire for value any or all of the Series A Preferred Stock. 
 7. Outstanding Shares. For purposes of this
Amended and Restated Certificate of Incorporation, after initial issuance, all shares of Series A Preferred Stock shall be deemed outstanding except (i) from the date, or the deemed date, of surrender of certificates evidencing shares of Series
A Preferred Stock, all shares of Series A Preferred Stock converted into Common 

 
Stock, (ii) from the date of registration of transfer, all shares of Series A Preferred Stock held of record by the Corporation or any subsidiary of the
Corporation and (iii) any and all shares of Series A Preferred Stock held in escrow prior to delivery of such stock by the Corporation to the initial beneficial owners thereof. 
 8. Status of Acquired Shares. Shares of Series A Preferred Stock received upon conversion pursuant to Section 4 or otherwise acquired
by the Corporation will be cancelled and shall not be reissued. 
 9. Preemptive Rights. The Series A Preferred Stock is not entitled
to any preemptive or subscription rights in respect of any securities of the Corporation. 
 10. No Amendment or Impairment. The
Corporation shall not amend its Certificate of Incorporation or participate in any reorganization, transfer of assets, consolidation, merger, dissolution, issue or sale of securities or any other voluntary action for the purpose of avoiding or
seeking to avoid the observance or performance of any of the terms to be observed or performed hereunder by the Corporation, but will at all times in good faith assist in carrying out all such action as may be reasonably necessary or appropriate in
order to protect the rights of the holders of the Series A Preferred Stock against impairment. 
 11. Severability of Provisions.
Whenever possible, each provision hereof shall be interpreted in a manner as to be effective and valid under applicable law, but if any provision hereof is held to be prohibited by or invalid under applicable law, such provision shall be ineffective
only to the extent of such prohibition or invalidity, without invalidating or otherwise adversely affecting the remaining provisions hereof. If a court of competent jurisdiction should determine that a provision hereof would be valid or enforceable
if a period of time were extended or shortened or a particular percentage were increased or decreased, then such court may make such change as shall be necessary to render the provision in question effective and valid under applicable law.

 FIFTH: The Board of Directors shall have the power to adopt, amend, alter or repeal the by-laws. 
 SIXTH: No director shall be personally liable to the Corporation or its stockholders for monetary damages for any breach of fiduciary duty by such
director to the fullest extent of the law. 
 SEVENTH: Unless and except to the extent that the bylaws of the Corporation shall so
require, the election of the directors of the Corporation need not be by written ballot. 
 EIGHTH: The Corporation reserves the right
at any time, and from time to time, to amend, alter, change or repeal any provision contained in this Certificate of Incorporation, and other provisions authorized by the laws of the State of Delaware at the time in force may be added or inserted,
in the manner now or hereafter prescribed by law; and all rights, preferences and privileges of whatsoever nature conferred upon stockholders, directors or any other persons whomsoever by and pursuant to this Certificate of Incorporation in its
present form or as hereafter amended are granted subject to the rights reserved in this Article. 

 IN WITNESS WHEREOF, the Corporation has caused this Amended and Restated Certificate of Incorporation to
be signed by its President this 26th day of June 2006. 
  

			
	INNOVIVE PHARMACEUTICALS, INC.
		
	By:	 	/s/ Steven Kelly
		 	Steven Kelly, President and CEO

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00106-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00106-of-00352.parquet"}]]